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Pancreatic ductal adenocarcinoma (PDAC) presents atmetastatic stage in over 50% of patients.With a survival rate of
just 2.7% for patients presenting with distant disease, it is imperative to uncover novel mechanisms capable of
suppressingmetastasis in PDAC. Previously, we reported that the loss of metastasis suppressor protein 1 (MTSS1) in
PDAC cells results in significant increase in cellular migration and invasion. Conversely, we also found that
overexpressingMTSS1 inmetastatic PDAC cell lines corresponds with not only decreasedmetastatic phenotype, but
also greater overall survival.While it is known thatMTSS1 is downregulated in late-stagePDAC, themechanismbehind
that loss has not yet been elucidated. Here, we build off our previous findings to present a novel regulatorymechanism
for the stabilization of MTSS1 via the tumor suppressor protein phosphatase and tensin homolog (PTEN). We show
that PTEN loss in PDAC cells results in a decrease in MTSS1 expression and increased metastatic potential.
Additionally, we demonstrate that PTEN forms a complex with MTSS1 in order to stabilize and protect it from
proteasomal degradation. Finally,we show that the inflammatory tumormicroenvironment,whichmakes upover 90%
of PDAC tumor bulk, is capable of downregulating PTEN expression through secretion of miRNA-23b, potentially
uncovering a novel extrinsic mechanism of MTSS1 regulation. Collectively, these data offer new insight into the role
and regulation of MTSS1in suppressing tumor cell invasion and migration and help shed light as to what molecular
mechanisms could be leading to early cell dissemination in PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of
cancer-related deaths in the United States with a 5-year survival rate of
9% [1,2].With research currently struggling to identify new biomarkers
and methods for earlier detection, most patients present with advanced
disease. Whereas 39% of PDAC patients present with regional or
distant disease, an astounding 53% of patients afflicted with PDAC are
diagnosed atmetastatic stage [3,4]. This accounts for 92% of all patients
diagnosed with PDAC being diagnosed after the primary tumor has
already spread. This phenomenon is due in part to the asymptomatic
nature of the disease and a lack of reliable early detection methods [5,6].
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be viable candidates for surgical resection, the treatment that still has the
best outcome for pancreatic cancer patients [7,8]. These challenges
combine to make PDAC an incredibly difficult disease to diagnose at
localized stage, thereby highlighting the importance of designing and
implementing innovative approaches to harness the disease before it is
able to spread. Specifically, elucidation of the molecular mechanisms
responsible for the early tumor cell dissemination observed in PDAC
that can lead to metastasis is an area that still requires much focus [9].
One of the molecular mechanisms that has recently been shown to
be critical for preventing tumor cell dissemination is the regulation of
metastasis suppressor protein 1 (MTSS1) [10]. Also known as
Missing in Metastasis (MIM), MTSS1 is believed to prevent
metastasis by increasing Rac-GTP levels in order to inhibit cell-cell
junction disassembly, thereby elevating actin assembly at the cell-cell
contacts and preventing cellular dissemination [11]. While very little
is known about the mechanism of action and molecular relationships
of MTSS1, it has been found to play a role in combatting cellular
migration and invasion in PDAC [10]. However, while the functional
role of MTSS1 in PDAC has recently been uncovered, the regulation
of MTSS1 in PDAC is still an enigma.
Multiple microRNAs have been shown to be capable of regulating
MTSS1 expression [12–15], whereas ubiquitination-driven destruction
and DNA methylation have also been found to play a role in MTSS1
downregulation as well [16–18]. Additionally, MTSS1 has also been
shown to have affinity for protein phosphatases, such as PTPδ and
PTPN11, in a range of different cancer subtypes [19,20]. The center of
the MTSS1 protein is rich in proline, serine, and threonine residues
[21]. These residues, all containing hydroxyl groups, interact and bind
with these phosphatases, which then may provide a functional link
between the MTSS1 protein and signal transduction pathways that
prevent an invasive state from arising. This interaction is intriguing
because one of the most commonly implicated tumor suppressors
involved in cancer progression is a phosphatase known as phosphatase
and tensin homolog (PTEN).
Here, we present evidence of a novel regulatory mechanism for
MTSS1 stabilization via the canonical tumor suppressor protein
PTEN. PTEN expression has been found to be crucial in minimizing
the lethality of PDAC through regulation of the PI3K/AKT pathway
[22]; however, its role in PDAC metastasis has only been briefly
studied [23–25]. In this manuscript, we demonstrate that loss of
PTEN in PDAC cells not only leads to a more invasive and migratory
phenotype, but also results in decreased in MTSS1 expression. We
find that PTEN positively regulates the stability and protein level of
MTSS1. Furthermore, we demonstrate that PTEN is a protein
phosphatase for MTSS1 and inhibits the interaction between MTSS1
and its E3 ligase SCFβ-TRCP to block the proteasome degradation of
MTSS1. Finally, we introduce a new, cell-extrinsic mechanism for the
downregulation of PTEN via miRNA-23b from the PDAC tumor
microenvironment, suggesting a novel role for both the tumor
microenvironment and PTEN in PDAC metastatic regulation.
Materials and Methods
Cell Culture and Transfection
Cancer-associated fibroblast (CAF) cell line UH1301-63 was
obtained fromMelissa L. Fishel, Ph.D. (Department of Pediatrics, IU
School of Medicine), and prepared for study as previously described
[26]. Fibroblast nomenclature was reduced for purposes of simplicity
with “S63” referring to UH1301-63 CAFs. Other commercial celllines were purchased from ATCC. S63, NIH3T3, PANC-1, MIA
PaCa-2, and 293T cells were cultured in DMEM supplemented with
10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin
with 5% CO2 at 37°C. Cells were trypsinized and passaged at
approximately 90% confluence. Cell transfection was performed
using Lipofectamine 2000 (Invitrogen), unless otherwise noted. Cells
were harvested at 24 hours post-transfection for protein analysis,
unless otherwise noted.
Cell Authentication
Fibroblast and epithelial cell lines were authenticated by Genetica
DNA Laboratories. All cell lines were a 97% to 100% match to the
correct cell line in both the ATCC and DSMZ database. The CAFs
were previously determined not to have a match in either database, were
non-tumorigenic in mice, and did not have a mutation for K-RAS [26].
Virus Production and Transduction
For overexpression of PTEN or MTSS1, 293T cells at 60%
confluence were transfected with retroviral plasmid (5 μg) containing
vector control, PTEN or MTSS1, VSVG (3 μg), and GAG (2 μg).
For knocking down PTEN or MTSS1, 293T cells at 60% confluence
were transfected with lentiviral plasmid (5 μg) containing Scramble,
shPTEN or shMTSS1, VSVG (3 μg), and GAG (2 μg). Virus was
collected 48 hours after transfection. Virus containing media was then
added to 70% confluent S63 or NIH3T3 cells supplemented with
polybrene (8 μg/ml). Stable cell pools were selected with puromycin
for 5 days. Verification was accomplished via Western blot analysis.
For shMTSS1, the following target sequence was used: GCTGATG
CATTGTGCATAT. The sequence was proven effective for both
human and mouse MTSS1 gene as previously described [27]. For
shPTEN, the following target sequence was used: CCACAAAT
GAAGGGATATAAA. The sequence was proven effective for both
human and mouse PTEN gene as previously described [28–31].
For shPTEN + MOE rescue experiments, 1.5 × 105 PANC-1
Scramble and shPTEN cells were plated in a 6-well setting. Twenty-four
hours post-plating, shPTENcells were transfectedwithMTSS1MycWT
plasmid (2 μg) using the Lipofectamine 3000 Transfection Reagent
(Thermo Fisher, L3000015) according to manufacturer's protocol.
Western Blotting Analysis
Protein lysates were prepared from S63, NIH3T3, PANC-1, MIA
PaCa-2, 293T, and stable cell pools in a buffer containing 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate,
1% NP-40, and1 mM EDTA supplemented with a protease inhibitor
cocktail tablet (Roche 11836153001). Cell lysate (40 μg) was resolved
by gel electrophoresis (BioRad Mini Protean TGX Gel 400091313)
and transferred to a nitrocellulose membrane. The membranes were
blocked in 5% dry milk in TBS-T. Primary antibodies diluted in 5%
dry milk and TBS-T include MTSS1 (Cell Signaling 4386S), PTEN
(Cell Signaling 9559S), phospho-Akt (Ser473) (Cell Signaling 4060S),
and β-actin (Cell Signaling 4970L) at 1:1000. Secondary antibodies
used include anti-rabbit (Cell Signaling 7074S). Protein levels were
detected by enhanced chemiluminescence (Thermo Scientific 32106)
and quantitated with Image Lab software (Bio-Rad). Densitometry
analysis was completed using ImageJ64 software.
For immunoprecipitation experiments, 500 μg of cell lysate was
incubated with IgG and Protein A–Agarose (SIGMA P2545) for
3 hours at 4°C. Beads were washed three times with lysis buffer and
centrifuged at 5000g for 5 minutes between each wash. Protein was
eluted from beads with 50 μl of Laemmli sample buffer (Bio-Rad).
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nitrocellulose for Western blotting.
For determining the phosphorylation status of MTSS1, the phos-tag
gel was used in which the phosphorylated MTSS1 ran slower than the
unphosphorylated MTSS1, as previously described [32].
Conditioned Media Collection
Media from cancer-associated fibroblasts (CAFM) or PANC-1 cells
[epithelial-conditioned media (EpM)] were collected after 3 to 4 days at
80% to 90% confluence and centrifuged at 2500 RPM for 5minutes in
order to pellet any debris. Media were stored at 4°C until needed.
Scratch Assay Analysis
Cells were seeded at 1.5 × 105 density in 6-well plates and allowed
to grow to 90% confluence. At 90% confluence, a scratch was made
down the center of the well using a P10 pipet tip. The cells were
washed with 1× PBS (Sigma) and then placed in the appropriate
media for 48 hours. Images were taken at 0, 12, 24, and 48 hours
posts-cratch using the AMG EVOS FL Cell Imaging System
microscope (AMEX4300). Analysis was completed in triplicate
using ImageJ64 software.
Transwell Assay Analysis
A total of 4 × 104 PDAC cells were plated on a 24-well Transwell
polycarbonate membrane with 8.0-μm pore size (Corning 3422).
Wells were coated with 50 μl of 3 mg/ml Matrigel (Corning 354230)
and kept at 37°C for 24 hours before plating to ensure solidification.
Cells plated in the upper chamber, unless treated with conditioned
media, were placed in 150 μl of the appropriate serum-free media,
whereas the bottom chamber contained 700 μl of the appropriate
serum-containing media to act as the chemoattractant in the study.
Cells were collected at 48 hours and gently rinsed with ddH2O and
then fixed for 20 minutes with 10% formalin (Azer Scientific). After
fixation, the cells were placed in hematoxylin (Sigma) for 2 minutes,
rinsed in ddH2O, quickly dipped in 1% acid alcohol (Sigma), and
rinsed a final time in ddH2O. Membranes were then imaged, and
individual cells were counted manually using an AMG EVOS XL
Core Cell Imaging System microscope (AMEX1000).
miRNA-23b Baseline and Inhibition Studies
PDAC cellular RNA was harvested using Trizol Reagent (Ambion
15596026) according to standard protocol. For formation of cDNA,
QIAGENmiScript II RT Kit (QIAGEN 218161) was used according to
manufacturer's protocol. Quantification of miRNA was completed using
the QIAGEN miScript SYBR Green PCR Kit (QIAGEN 218073)
according to manufacturer's protocol on the Bio-Rad CFX Connect
Real-Time PCR Detection System (Bio-Rad). The following miRNA
primer assays from QIAGEN were purchased and utilized:
Hs_RNU6-2_11 (QIAGENMS00033740),Hs_miR23b_2 (QIAGEN
MS00031647), and Hs_miR23a_2 (QIAGENMS00031633). miRNA
was normalized to RNU6.
miR-23b inhibition studies were completed according to QIAGEN
miScript miRNA Inhibitor protocol. Briefly, 1.0 × 105 PANC-1 cells
were plated and incubated while the inhibitor cocktails were prepared.
The following miRNA inhibitors were added to the appropriate
serum-free culture medium at a final concentration of 50 nM: Negative
Control siRNA (QIAGEN SI03650325) and Anti–hsa-miR-23b-3p
(QIAGEN MIN0000418). HiPerfect Transfection Reagent (QIA-
GEN 301707) was used to complete the transfection cocktail. Cells
were harvested and/or experimented with at 48 hours post-transfection.Patient Dataset Analysis
The prognostic value of PTENandMTSS1 loss in PDACpatients was
analyzed in a publically available dataset, GSE21501 [33], using
PROGgene gene expression–based survival analysis web application [34].
RNA Collection RT-PCR Analysis
RNA was harvested with Trizol (Life Technologies), resuspended in
RNAse-free water, and analyzed for purity by 260/280 absorbance via
Nanodrop. RT-PCR was conducted on the BioRad-CFX-Connect
cycler using Qiagen QuantiFast SYBR Green RT-PCR kit (Qiagen
204154) and the following primers: Human GAPDH (Qiagen
PPH00150F) and Human MTSS1 (Qiagen PPH10073B).
Statistical Analysis
Experiments were performed with a minimum of three biological
replicates. Data are presented as the mean ± standard deviation.
Statistical significance was calculated via Microsoft Excel using a
Student t test. “*” denotes P value b .05, “**” denotes P value b .001,
and “***” denotes P value b .0001.
Results
Loss of PTEN In Vitro Results in Increased PDAC Cellular
Invasion and Migration
In order to investigate our hypothesis that the phosphatase activity of
PTEN stabilizes MTSS1 expression in PDAC, we first set out to define
the importance of PTEN itself in pancreatic cancer metastatic
progression. While there is strong supporting evidence that PTEN
plays a large role in suppressing tumor formation and growth in PDAC
[35–37], its role in metastasis is less well known. Utilizing a stably
transduced PANC-1 PDAC cell line to knock down PTEN expression,
we were able to run a number of assays to determine if PTEN played a
role in PDAC invasion and migration. PANC-1 shPTEN cells display
84% knockdown of PTEN compared to PANC-1 Scramble control
(Figure 1A, Supplemental Figure 1). PANC-1 shPTEN cells exhibit
significantly increased migration and invasion capabilities when
compared to control in both serum-free and serum-containing scratch
assay settings (Figure 1B). In serum-free conditions, where cells are not
able to proliferate but rather must rely on migratory properties to travel
across the wound, PANC-1 shPTEN cells were able to migrate
approximately 100 μm farther than Scramble control. Similarly, in
serum-containing conditions, PANC-1 shPTEN cells were able to
invade across the wound approximately 200 μm farther than Scramble
control over a 48-hour period.
Next, knowing the importance of the tumor microenvironment on
PDACmetastatic progression [9,38,39], we investigated how treatment
with media taken from CAFs, which are the main component of the
PDAC tumor microenvironment, affected PTEN expression in
PANC-1 cells. Western blot analysis revealed that PANC-1 cells treated
with CAFM at various lysate collection points express diminished levels
of PTEN expression and increased levels of P-AKT (Figure 1C). At the
24-hour lysate collection time point, PTEN expression in
CAFM-treated PANC-1 cells was reduced by approximately 35%,
whereas at the 48-hour collection time point, that reduction in PTEN
expression in CAFM-treated cells rose to approximately 45%
(Supplemental Figure 1). CAFM treatment also resulted in an increase
in P-AKT expression. At the 24-hour lysate collection time point,
CAFM-treated PANC-1 cells express 86% more P-AKT than
EpM-treated PANC-1 cells. Furthermore, at the 48-hour collection
time point, that increase rose to 95% (Supplemental Figure 2).
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ability to increase invasion and migration, PANC-1 shPTEN cells were
incubated in either EpM or CAFM and subjected to scratch assay
analysis. PANC-1 shPTEN cells travel approximately 50 μm farther
than Scramble control in EpM conditions; however, when incubated in
CAFM conditions, PANC-1 shPTEN cells travel greater than 150 μm
farther than Scramble control (Figure 1D). Additionally, the PANC-1
shPTEN cells were plated in a Matrigel-coated Transwell membrane
and incubated in either EpM or CAFM. PANC-1 shPTEN cells
incubated in EpM were 1.64-fold more successful at invading through
the Matrigel-coated membrane than Scramble control, whereas
PANC-1 shPTEN cells incubated in CAFM were 2.8-fold moreFigure 1. Loss of PTEN results in increased invasion and migration. (A
compared to Scramble control. (B) PANC-1 Scramble and shPTEN
serum-free (top) and serum-containing (bottom) conditions. PANC-1
farther than PANC-1 Scramble cells in both conditions. (C) PANC-1 ce
timepoints. Lysates were analyzed via Western blot, and it was seen
went on, which was accompanied by a robust upregulation of P-AKT.
assay was performed in either EpM or CAFM conditions. PANC-1 shP
phenomenon was augmented in the presence of CAFM, in which t
PANC-1 Scramble control cells. (E) PANC-1 Scramble and shPTEN ce
either EpM or CAFM conditions. PANC-1 shPTEN cells invaded sig
significance was increased in shPTEN cells cultured in CAFM. (F) Wes
MTSS1 expression decreases in PANC-1 shPTEN cells. (G) West
(primPDAC.1) PDAC patient cell lysates shows metastatic patient sam
b .05, **P value b .001, ***P value b .0001.successful at invading through the Matrigel-coated membrane than
PANC-1 Scramble control (Figure 1E).
Having established that loss of PTEN in PDAC epithelial cells results
in increased metastatic potential, we next investigated if loss of PTEN
affected MTSS1 expression. PANC-1 shPTEN cells exhibit approxi-
mately 80%decrease inMTSS1 expression when compared to Scramble
control (Figure 1F). Additionally, we performed Western blot analyses
on both primary (primPDAC.1) and metastatic (metPDAC.1) PDAC
patient cell lysates. metPDAC.1 cells displayed a nearly two-fold
decrease in PTEN expression levels when compared to primPDAC.1
cells (Figure 1G). The metastatic patient cells also showed a robust
9.9-fold decrease in MTSS1 expression as compared to the primary) Western blot confirmation of stable PANC-1 shPTEN cell pool as
cells were plated, and a scratch assay was performed in both
shPTEN cells were able to move across the scratch significantly
lls were cultured in PANC-1 EpM or CAFM and harvested at various
that PANC-1 cells cultured in CAFM expressed less PTEN as time
(D) PANC-1 Scramble and shPTEN cells were plated, and a scratch
TEN cells traveled significantly farther across the scratch, and that
he PANC-1 shPTEN cells traveled more than two-fold farther than
lls were plated, and a Transwell invasion assay was performed in
nificantly more through the Transwell membrane; however, that
tern blot analysis of PANC-1 Scramble and shPTEN cells shows that
ern blot analysis of both metastatic (metPDAC.1) and primary
ple containing decreased PTEN and MTSS1 expression. *P value
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loss significantly increases PDAC cell migration and invasion,
potentially due to the downregulation of MTSS1 expression. To
provide additional validation of this finding, we examined a publically
available PDAC patient dataset, GSE21501, to determine if loss of
both PTEN and MTSS1 expression correlated with patient outcome.
We found that decreased expression levels of both PTEN and MTSS1
were a significant predictor of poorer overall patient survival (HR: 0.59,
P = .0240028; Supplemental Figure 3).
PTEN Stabilizes MTSS1
Having previously established that stable MTSS1 expression levels
are correlated with decreased metastatic potential in PDAC [10] and
now having uncovered a potential novel connection between the PTEN
tumor suppressor andMTSS1 status, we next investigated the potential
molecular mechanism that could be responsible for the loss of PTEN
correlating to loss of MTSS1. We hypothesized that PTEN might
regulate both the MTSS1 protein level and stability. To test this
hypothesis, wemanipulated PTENexpression levels by transfecting S63
PDAC fibroblast cells with either a plasmid that produces overexpres-
sion of PTEN (PTEN) or a plasmid that knocks down PTEN
expression (shPTEN). We observed that overexpression of PTEN
significantly increases MTSS1 expression, whereas knockdown of
PTEN significantly decreases MTSS1 expression in S63 cells compared
to a vector only control (Figure 2A).Figure 2. PTEN stabilizes MTSS1 expression levels. (A) MTSS1 protei
overexpression increases MTSS1 protein level, and PTEN knockdown
transfectedwith control, PTEN, or shPTEN,wereanalyzedbyWestern b
MTSS1 stability in S63 cells. S63 cells stably expressing vector or PTEN
MTSS1 protein levels were determined. Relative MTSS1 levels were no
out in NIH3T3 fibroblast cells and showed similar results. Data are repNext, we used retroviruses to generate S63 cell pools that stably
overexpressed either PTEN or vector-only control (Supplemental
Figure 4). When the stability of MTSS1 was compared between these
cell pools, we observed that overexpression of PTEN significantly
increases MTSS1 stability in S63 cells treated with the protein synthesis
inhibitor cyclohexamide (CHX) in media with serum (Figure 2B). To
further confirm our findings in a general fibroblast cell line, the same
assays were performed in NIH3T3 cells. We observed that overexpres-
sion of PTEN significantly increases MTSS1 protein level in NIH3T3
cells, while PTEN knockdown significantly decreases MTSS1 protein
levels (Figure 2C). Finally, we observed that PTEN overexpression
significantly increases MTSS1 stability in NIH3T3 cells, matching
what we had observed in S63 cells (Figure 2D). Collectively, our data
show that MTSS1 stability—and thereby protein level—is positively
regulated by PTEN.
PTEN Is a Protein Phosphatase for MTSS1
Thus far, our data show that PTEN regulates MTSS1 in human
pancreatic cancer cells as well as mouse fibroblasts. We next sought to
elucidate which of PTEN's many functions is responsible for this
regulation. PTEN is a tumor suppressor that acts as both a lipid
phosphatase and a protein phosphatase [40]. As part of its role as a
lipid phosphatase, PTEN negatively regulates the intracellular levels
of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a
tumor suppressor by negatively regulating the PI3K/AKT signalingn level is positively regulated by PTEN in S63 fibroblast cells. PTEN
decreases MTSS1 protein level. Cell lysates of S63 cells, which were
lot.MTSS1 levelswerenormalized againstβ-actin. (B) PTEN increases
were treated with CHX (20 μg/ml) for indicated times. Endogenous
rmalized against β-actin. In (C) and (D), the same assays were carried
resented as mean ± SEM. *P value b .05, **P value b .001.
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pathway may negatively regulate MTSS1 protein expression.
To test this hypothesis, we treated S63 and NIH3T3 cells with
LY294002, a PI3K inhibitor that specifically mimics the lipid
phosphatase activity of PTEN [42]. Surprisingly, we found that while
LY294002 treatment decreased P-AKT levels, it did not significantly
increase MTSS1 levels in either S63 or NIH3T3 cells (Figure 3A).
However, when we transfected PPP577 cells, which are a murine cell
line that are Pten−/−, with a plasmid that mutated only the lipid
phosphatase activity of Pten (PtenG129E), leaving only the protein
phosphatase activity as viable, we found that the cells with Pten
protein phosphatase activity were able to not only stabilize Mtss1
protein levels but in fact moderately increase Mtss1 expression by
approximately 30%, unlike what we saw in Figure 3A (Supplemental
Figure 5, lanes 1 and 3). These results suggest that PTEN regulates
MTSS1 specifically through its protein phosphatase activity and not
its lipid phosphatase activity.
Given that it is not uncommon for dephosphorylation events
between a phosphatase and its target protein to occur via physical
interaction, we hypothesized that PTEN was exerting its phosphatase
activity on MTSS1 through a direct physical interaction. Hence, weFigure 3. PTEN is a protein phosphatase for MTSS1. (A) In both S63
MTSS1 protein level. Cells were treated with PI3K inhibitor LY29400
included as indicator of increased MTSS1. S473 (pAKT) was detect
analyzed by Western blot. Panels (B) and (C) show that PTEN and MT
with MTSS1 into 293T cells as indicated. (C) Myc-MTSS1 was transfec
reciprocal co-IP as indicated. “^” indicates the presence of the heavy
MTSS1. PTEN was co-transfected with MTSS1 or MTSS1S322A into
determined by the phos-tag gel. Data are represented as mean ± SEperformed co-immunoprecipitation (co-IP) experiments with ectopi-
cally expressed proteins to determine whether PTEN could bind with
MTSS1.We found that ectopic expression of Flag-tagged PTEN could
be readily pulled down by Myc-MTSS1 (Figure 3B). Similarly,
reciprocal co-IP experiments also showed that Myc-MTSS1
co-precipitated with endogenous PTEN (Figure 3C). Taken together,
these results show that MTSS1 and PTEN are, at the very least, in the
same protein complex, consistent with our hypothesis that MTSS1 is a
substrate for PTEN's phosphatase activity.
To further test this hypothesis, we next wanted to investigate whether
PTEN actually alters the phosphorylation level of MTSS1 via Western
blot analysis. However, due to the lack of an antibody that can detect
phosphorylated MTSS1, we could not evaluate the phosphorylation
level of MTSS1 directly. Therefore, we used Phos-tag SDS-PAGE
analysis to detect the phosphorylation change of MTSS1. In a Phos-tag
gel, phosphorylated proteins run slower than unphosphorylated
proteins. Thus, if two bands are observed in a sample, the lower band
corresponds to the unphosphorylated form of the protein, and the
upper band corresponds to the phosphorylated form of the protein.
When we ectopically expressed MTSS1 alone in 293T cells, the lower,
unphosphorylated band for MTSS1 was faint, but upon co-expressionand NIH3T3 fibroblast cells, inhibition of PI3K does not increase
2 (30 μM) for 6 hours. MG132 (10 μM for 6 hours) treatment was
ed as positive control for LY294002 treatment. Cell lysates were
SS1 are in the same protein complex. (B) PTEN was co-transfected
ted in 293T cells. PTEN andMTSS1 associations were examined by
chain of rabbit IgG. (D) PTEN decreases the phosphorylation level of
293T cells as indicated. The phosphorylation level of MTSS1 was
M.
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was seen clearly (arrow in Figure 3D, left panel). This suggests that
PTEN can decrease MTSS1 phosphorylation levels.
Finally, we sought to identify a phosphorylation site on MTSS1
that would mediate its interaction with PTEN. Previous literature has
shown not only that the serine 322 residue (S322) on MTSS1 is
phosphorylated by kinase CKIδ, but that phosphorylated S322 is
necessary for MTSS1 proteasome degradation [16]. We therefore
hypothesized that PTEN might be responsible for dephosphorylating
the S322 residue of MTSS1, thereby protecting it from proteasome
degradation and thus stabilizing its expression. To test this
hypothesis, we ectopically expressed a form of MTSS1 that harbors
a point mutation at residue 322 from serine to alanine (MTSS1S322A)
in 293T cells. These cells were co-transfected with or without PTEN
in order to see whether PTEN could still alter the MTSS1
phosphorylation level despite a mutation at the S322 site. The data
show that there is no significant difference between the upper,
phosphorylated band and lower, unphosphorylated band with or
without overexpression of PTEN (Figure 3D, right panel). This
suggests that the S322 residue could be the dephosphorylation site
through which PTEN stabilizes MTSS1.Figure 4. PTEN blocks proteasome degradation of MTSS1. (A and B) M
levels in both S63 and NIH3T3 fibroblast cells. S63 and NIH3T3 fibrob
MG132 (10 μM) for 6 hours. Endogenous MTSS1 protein levels were
plasmids were transfected into 293T cells. Co-IP was performed t
overexpressing PTEN, the interaction betweenMTSS1 and β-TrCP decr
interaction between MTSS1S322A and β-TrCP. (E) MG132 blocks PTEN
lines. PANC-1 and MIA PaCa-2 epithelial cells transfected with Scra
EndogenousMTSS1 protein levels were determined along with the β-aPTEN Blocks Proteasome Degradation of MTSS1
While MTSS1 has been linked to the regulation of metastasis in
various cancer types, most of the published studies have focused on the
transcriptional regulation of MTSS1 [43,44]. The only previous study
that examined posttranslational regulation of MTSS1 found that
ubiquitination of MTSS1 by SCFβ-TRCP promotes its proteasome
degradation [16]. Our data showing that PTEN stabilizes MTSS1 levels
in cells exposed to CHX indicate that PTEN regulates MTSS1 in a
posttranslational manner because CHX interferes with translational
elongation. Additionally, we found that while our shPTEN cells did in
fact express decreased levels ofMTSS1, the difference was not significant,
further indicating a need to investigate the novel PTEN/MTSS1
relationship at the translational level (Supplemental Figure 6). Thus, to
elucidate whether PTEN regulates MTSS1 through proteasome
degradation, we treated S63 and NIH3T3 cells with MG132, a
proteasome inhibitor, combined with knockdown of PTEN. In both
S63 andNIH3T3 cells, the decrease ofMTSS1 protein levels induced by
knockdown of PTEN is significantly blocked by MG132 (Figure 4, A
and B). These results suggest that PTEN has the same effect on MTSS1
protein level as MG132 in that they both prevent the proteasome
degradation of MTSS1.G132 blocks PTEN knockdown-induced decrease of MTSS1 protein
last cells stably expressing Scramble or shPTEN were treated with
determined along with the β-actin control. (C and D) The indicated
o determine the interaction between MTSS1 and β-TrCP. When
eased in reciprocal co-IP. Overexpression of PTENdoes not affect the
knockdown-induced decrease of MTSS1 protein levels in PDAC cell
mble or shPTEN were treated with MG132 (10 μM) for 6 hours.
ctin control. Data are represented asmean ± SEM. **P value b .001.
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with the E3 ligase SCFβ-TRCP and phosphorylation at the S322
residue [16]. Having earlier shown that PTEN is a phosphatase for
MTSS1 and that the S322 residue may be the dephosphorylation site
for PTEN, we next sought to show that MTSS1 protein level change
occurs through SCFβ-TRCP. Our results show that overexpression of
PTEN decreased the binding between β-TrCP and MTSS1 but did
not change the binding between β-TrCP and MTSS1S322A (Figure 4,
C and D). This is consistent with our earlier results showing that
PTEN decreases the phosphorylation level of MTSS1 but not the
phosphorylation level of MTSS1S322A.
Until this point, our data on MTSS1 regulation via PTEN had
been completed in 293T cells and multiple fibroblast cell lines.
However, we still wanted to determine whether PTEN stabilizes
MTSS1 in a similar way in epithelial PDAC cells [45]. Thus, we
performed the same experiments with PANC-1 and MIA PaCa-2
cells, two epithelial PDAC cells lines that have been previously used
by our laboratory [10]. We observed that PDAC cells with PTEN
knockdown showed similar results when they were treated with
MG132 (Figure 4E), indicating that this novel regulation of MTSS1
by PTEN happens in both CAFs and PDAC cells.Figure 5. Increase in MTSS1 expression results in decreased invasion
transducedwith either Scramble control vector or shPTEN knockdown
Myc-MTSS1 plasmid, andMTSS1 overexpressionwas confirmed viaW
were plated, and a scratch assaywas performed in both serum-free (top
in PTEN expressionmoved significantly further across thewound in bot
there was no significant difference denoted when compared to Scramb
wereplated, and aTranswell invasion assaywasperformed in thepresen
significantly more often than Scramble control until MTSS1 was overex
**P value b .001.Increase in MTSS1 Expression Results in Decreased Metastatic
Phenotype in PTEN-Deficient Cells
Thus far, our data show that PTEN status in PDAC cells correlates
withMTSS1 expression levels.We have identified that loss of PTEN has
not only significant functional consequences through increasing cellular
migration and invasion capabilities but also significant molecular
consequences in that its loss allows for MTSS1 to be tagged for
proteasomal degradation. However, we wanted to further test our
hypothesis that MTSS1 is a target of PTEN through functional rescue
experiments. Utilizing the same PANC-1 shPTEN cell lines from our
previous experiments, we transiently transfected Myc-MTSS1 plasmid
into the cells in order to generate a cell line that was deficient in PTEN
yet still expressed MTSS1 (Figure 5A). We then took these cells and
performed a scratch assay in either the presence or absence of serum in
order to functionally define the importance of MTSS1 in a
PTEN-deficient setting. In serum-free conditions, PANC-1 shPTEN
cells were still significantly more able to migrate across the scratch by
approximately 50 μm farther than either Scramble control or shPTEN +
MOE cells (Figure 5B). However, upon rescue withMTSS1, shPTEN +
MOE cells displayed a significantly less migratory phenotype even when
compared to PANC-1 Scramble, indicating a reversion to a moreand migration in PTEN-deficient cells. (A) PANC-1 cells were stably
plasmid. PANC-1 shPTEN cells were then transiently transfectedwith
estern blot. (B) PANC-1 Scramble, shPTEN, and shPTEN+MOE cells
) and serum-containing (bottom) conditions. Cells thatwere deficient
h conditions, but upon overexpression ofMTSS1 in those same cells,
le control. (C) PANC-1 Scramble, shPTEN, and shPTEN+MOE cells
ce ofMatrigel. PANC-1 shPTENcells invaded through themembrane
pressed, and then no significant difference was seen. *P value b .05,
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conditions, where PANC-1 shPTEN cells invaded approximately
150 μm farther than both Scramble and shPTEN + MOE cells
(Figure 5B). Still, the rescue shPTEN+MOE cells once again reverted to
amore stationary phenotype, in which there was no significant difference
seen between the Scramble and shPTEN + MOE cell lines.
Additionally, these cell lines were plated in Matrigel-coated wells
for Transwell invasion analysis. PANC-1 shPTEN cells invaded
through the Transwell membrane significantly more often than either
Scramble or shPTEN +MOE cells (Figure 5C). However, even in the
absence of PTEN, the PANC-1 shPTEN + MOE cells were able to
return to a similar invading cell number as PANC-1 Scramble control
cells, as there was no significant difference seen between the two cell
lines. These data indicate the crucial presence of MTSS1 in PDAC
progression. We show that even if an important tumor suppressor,
such as PTEN, is lost, as long as MTSS1 is still present, the ability for
a cell to migrate and invade is diminished significantly.
Inhibition of miRNA-23b Leads to Decreased Metastatic
Phenotype and Increased PTEN and MTSS1 Expression
While all of our data thus far have been focused on the cell-intrinsic
regulation of MTSS1 through the tumor suppressor PTEN, we have
also presented evidence indicating a potential cell-extrinsic role for the
CAFs found in the tumor microenvironment (Figure 1, D and E).
One of the avenues that we hypothesized may play a role in the
downregulation of MTSS1 via PTEN loss was miRNA regulation. It
is well documented that MTSS1 is a target for downregulation of
many miRNAs [12–15]. However, we chose to investigate miRNAs
that target PTEN in order to determine if miRNA regulation of
PTEN played any role on MTSS1 expression. One such miRNA
cluster, the miR-23 cluster, has been reported to inhibit PTEN gene
expression in a number of different cancer models [46–48]. Upon
further investigation, we found that one specific member of the
miR-23 cluster, namely, miR-23b, is predicted to target the 3′ UTR
of PTEN with an miTG score of 0.824 (Figure 6, A and B).
Having determined that miR-23b would be an appropriate
upstream inhibitor of PTEN, we next sought out to define the
relative expression level of miR-23b in a PDAC epithelial cell line
versus a PDAC CAF cell line. qPCR analysis revealed that PDAC
CAFs have a nearly 12-fold higher miR-23b expression level than
epithelial PDAC cells (Figure 6C). We also transiently transfected a
plasmid containing two members of the miR-23 cluster, namely,
miR-23b and miR-27b, into PANC-1 cells and performed a Western
blot on their lysates. In PANC-1 cells transfected with miR-23b27b,
PTEN expression was dramatically decreased when compared to
MiArrest control (Figure 6D).
Upon uncovering a potential link between miR-23b expression
and PTEN status, we next sought to investigate the functional and
genomic repercussions of inhibiting miR-23b. Utilizing transiently
transduced PANC-1 cell lines that were treated with anti–miR-23b
(Figure 6E), we performed a scratch assay to determine the effects of
diminishing miR-23b expression levels. PANC-1 anti–miR-23b cells
were significantly less able to invade across the wound, traveling
approximately 100 μm less than (−) control (Figure 6F). Additionally,
these PANC-1 anti–miR-23b cells were 1.7-fold less able to travel
through a Matrigel-coated Transwell membrane when compared to
(−) control, indicating miR-23b's importance in promoting cellular
invasion and migration (Figure 6G). In order to investigate the
genomic consequences of miR-23b loss, we treated PANC-1 cellswith either (−) control or anti–miR-23b inhibitor and found that
inhibition of miR-23b results in a moderate increase in both MTSS1
and PTEN status (Figure 6H).
Together, these data suggest a novel, cell-intrinsic mechanism for the
regulation of MTSS1 via the protein phosphatase activity of PTEN.
However, we hypothesize that there is also a cell-extrinsic component to
this regulation, specifically through the transfer of miR-23b from the
PDACCAFs of the tumor microenvironment to the tumor epithelium,
wheremiR-23b targets PTEN for downregulation, leading to the lack of
protection for MTSS1 from proteasomal degradation, thus causing an
increase in cellular invasion and migration (Figure 6I).
Discussion
In this report, we uncover a new mechanism of regulating MTSS1
stability via the protein phosphatase activity of PTEN.This regulation is
essential for suppressing pancreatic cancer cell invasion and migration.
We previously identified MTSS1 as a metastasis suppressor protein
crucial for keeping cells from further disseminating from the primary
tumor [10]. Upon validating its functional role in PDAC, we sought to
determine novel ways in whichMTSS1 could be regulated in pancreatic
cancer. Knowing the affinity that the MTSS1 protein has for protein
phosphatases, we began our investigation looking at the role that PTEN
plays in PDAC metastatic progression. We showed that loss of PTEN
significantly increases PDAC cell migration and invasion, while at the
same time resulting in decreased expression of MTSS1. Next, we
demonstrated that CAF-conditioned medium has the ability to increase
the migratory and invasive properties of PTEN-deficient cells. We then
provided evidence to support our hypothesis that PTEN stabilizes
MTSS1 via its protein phosphatase activity. Through dephosphoryla-
tion of the S322 residue of MTSS1, PTEN decreases the binding
betweenMTSS1 and its E3 ligase SCFβ-TRCP to prevent the proteasome
degradation of MTSS1. We also showed that, even in the absence of
PTEN in PDAC cells, ectopic expression of MTSS1 was able to revert
cells to a more stationary phenotype. Finally, we offered a novel,
cell-extrinsic mechanism of how PTEN downregulation occurs via
miR-23b in the PDAC tumor microenvironment, leading to eventual
loss of MTSS1 expression.
Metastasis is a significant contributor to mortality in cancer patients,
especially in PDAC due to its late diagnosis [49]. MTSS1 is a metastasis
suppressor gene originally identified as a protein downregulated in
metastatic bladder carcinoma cell lines [50]. Growing evidence exists
showing that downregulation of MTSS1 expression correlates with
metastatic progression in a number of cancers, including bladder,
prostate, breast, and pancreatic cancer [43,44,51,52]. In our previous
study, we have shown that loss ofMTSS1 results in increased metastatic
potential in pancreatic cancer [10]. Maintaining robust MTSS1
expression levels is difficult, especially in late-stage cancers, where it
has been found that MTSS1 is frequently downregulated [50–54].
Therefore, uncovering the molecular mechanisms responsible for
regulating MTSS1 expression is crucial for combatting cancer cell
dissemination.
A number of different studies have been completed looking at the
different regulatory mechanisms of action for manipulating MTSS1
expression levels. Most commonly,MTSS1 is found to be the target of a
small number of miRNAs that are capable of downregulating its
expression. In squamous cellular carcinoma, miR-96 was found to target
and downregulate MTSS1 expression, leading to increased cellular
proliferation and metastasis [55]. Similarly, miR-135b in colorectal
cancer [13], miR-182 in ovarian cancer [56], and miR-135a in
Figure 6. Manipulation of miRNA-23b leads to altered cellular invasion, migration, and PTEN and MTSS1 expression. (A) Schematic of
miR-23b binding site in PTEN mRNA 3′ UTR sequence at nucleotide position 1608 to 1615. (B) DIANA LAB miTG prediction score of the
probability that miR-23b will target PTEN. The closer to 1.0 the miTG score, the higher the probability of targeting. (C) qPCR analysis of
relative miR-23b expression levels in PDAC epithelial cells or PDAC CAFs. (D) PANC-1 cells were transiently transfected with miR-23b27b
cluster plasmid. These cells showed robust loss of PTEN expression upon Western blot examination. (E) qPCR confirmation of PANC-1
cells transiently transfected with anti–miR-23b inhibitor. (F) PANC-1 cells treated with anti–miR-23b were significantly less able to travel
across the wound in a scratch assay setting as compared to (−) control. (G) PANC-1 cells treated with anti–miR-23b were significantly less
able to travel through a Matrigel-coated membrane in a Transwell invasion assay setting as compared to (−) control. (H) Treatment of
PANC-1 cells with anti–miR-23b resulted in an increase in expression levels of both PTEN and MTSS1 as confirmed via Western blot
analysis. (I) Schematic for the hypothesized mechanism of action for the downregulation of MTSS1 via PTEN loss. The dense tumor
microenvironment, majorly composed of CAFs, contains higher amounts of miRNA-23b. miRNA-23b is then secreted to the PDAC tumor
epithelium, where it targets PTEN, downregulating it. This downregulation leaves MTSS1 unstabilized from proteasomal degradation and
thus results in loss of MTSS1 and thereby increased metastatic potential. *P value b .05, **P value b .001, ***P value b .0001.
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downregulate MTSS1 expression, leading to increased metastatic
potential. Additionally, MTSS1 has been found to be a target of
methylation-induced silencing [18,58]. Interestingly, all of these
aforementioned studies looking into the regulation of MTSS1 occur
during pre-translational phases, that is, at the transcriptional, mRNA
level. Instead of taking that canonical approach to this particular
regulatory situation, we hypothesized that the protein structure of
MTSS1 may lead to novel regulatory opportunities.
MTSS1 is a multidomain, scaffold protein that normally regulates
cytoskeletal dynamics and actin polymerization of the cell [21,59]. As a
multidomain protein, MTSS1 contains a WH2 [WASP (Wiskott-
Aldrich syndrome protein) homology 2] domain and an IMD [IRSp53
(insulin receptor substrate protein of 53 kDa) and MIM homology]
domain to help develop the cytoskeletal interactions necessary topromote cellular adhesion [59]. However, the relevant portion of the
MTSS1 protein to this study is the center due to its wealth of proline,
serine, and threonine residues. These residues, all containing hydroxyl
groups, are prime targets for interactions with a number of different
proteins, specifically including phosphatases like PTEN.
PTEN is a well-studied tumor suppressor that negatively regulates
the PI3K/AKT pathway [40,41]. Many publications have shown that
PTEN inhibits tumor cell proliferation, migration, and invasion
[60–65]. While many of these studies have focused on how PTEN's
regulation of AKT signaling limits oncogenic potential, no publication
to date has established a novel connection between the PTEN tumor
suppressor and the MTSS1 metastasis suppressor. Our data define a
functional relevance for PTEN loss in the metastatic progression of
PDAC, as PTEN-deficient cells were more invasive and migratory in
nature. Additionally, the PTEN-deficient cells also harbor decreased
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a lipid phosphatase, in this context, PTEN's protein phosphatase
activity is responsible for stabilizing MTSS1.
Previous data have shown MTSS1 to be vulnerable to proteasome
degradation via phosphorylation of its Ser322 residue [16]. The
hydroxyl group of the Ser322 residue undergoes a phosphorylation
event by casein kinase 1δ. That phos-tagged Ser322 essentially
becomes a beacon for ubiquitination via the 26S proteasome. Zhong
et al. noted in their study that phosphatase interaction could disrupt
this ubiquitination event, but they did not stipulate further as to
which phosphatase, if any, may be critical to this stabilization
of MTSS1. Here, for the first time, we provide data showing that
PTEN can protect MTSS1 from proteasome degradation via
dephosphorylation of this S322 residue, thus stabilizing its expression
levels. Our data do not show PTEN or MG132 having the ability to
significantly increase MTSS1 expression levels, although they are both
acting in ways that are meant to disrupt the proteasomal degradation of
MTSS1. This correlates with our initial hypothesis that PTEN plays a
role in simply stabilizing MTSS1 expression, not necessarily increasing
it. Through the dephosphorylation activity of PTEN or through
proteasomal inhibition via MG132, MTSS1 is protected from
degradation, and simply by maintaining normal levels of MTSS1
expression, we showed that cellular invasion and migration are
significantly diminished.
While the majority of the data presented here strongly supports our
hypothesis that PTEN stabilizes MTSS1 in a cell-intrinsic fashion, we
also present results that suggest that the dense tumormicroenvironment
that is characteristic of PDAC also plays a cell-extrinsic role in regulating
MTSS1 expression. CAFs make up the majority of cells that comprise
the tumor microenvironment in PDAC [38,66,67]. Based on our prior
MTSS1 studies, we know that CAFM leads to a robust downregulation
of MTSS1 expression [10]. In this study, we found that CAFM is
capable of downregulating PTEN expression as well. Thus, we
hypothesized that something secreted by the CAFs into their media
was responsible for the downregulation of both PTEN and MTSS1.
Since we found PTEN to be the protein responsible for the stabilization
of the expression level ofMTSS1, we focused our attention on potential
regulators of the phosphatase protein that were found in the CAFM.
One of the better-studied inhibitors of PTEN in prior reports has been
the miRNA-23 cluster [46–48]. We found that one specific member of
this miRNA cluster, namely miR-23b, was significantly upregulated in
CAFs as compared to PDAC epithelial cells. Upon overexpression of
this miRNA in PANC-1 PDAC epithelial cells, we noticed complete
ablation of PTEN expression. Conversely, whenwe inhibitedmiR-23b,
we found that not only did cellular migration and invasion decrease, but
also both PTEN and MTSS1 expression increased moderately.
These data suggested to us that the CAFs found in the PDAC tumor
microenvironment may be secreting miR-23b, which is finding its way
to the tumor epithelium, where it is targeting PTEN for downregu-
lation. This downregulation of PTEN causes the destabilization of
MTSS1, allowing its Ser322 residue to be phosphorylated by casein
kinase 1δ, thus tagging it for proteasomal degradation. This novel,
cell-extrinsic mechanism compiled with our original finding of a
regulatory relationship between the canonical tumor suppressor PTEN
and the metastasis suppressor MTSS1 offers new insight into one of the
controlling mechanisms at hand in PDAC metastatic progression.
Future studies will focus further on how other members of the
miRNA-23 cluster may impact PDAC metastasis as well as uncovering
other factors in the tumor microenvironment that may be responsiblefor perpetuating increased metastatic characteristics in PDAC.
Additionally, in vivo analyses showing that PTEN inhibits tumor
growth and invasion via the MTSS1 pathway will be critical in further
supporting these findings.
In conclusion, our findings support our central hypothesis that
MTSS1 is stabilized by the protein phosphatase activity of the tumor
suppressor PTEN.Our data show that PTEN loss in PDAC cells results
in both increasedmetastatic potential and decreasedMTSS1 expression.
Furthermore, we show that ectopic MTSS1 expression rescues this
effect. Additionally, we demonstrate that PTEN forms a complex with
MTSS1 in order to stabilize it from proteasomal degradation. Finally,
we show that the tumor microenvironment, which makes up over 90%
of PDAC tumor bulk, is capable of downregulating PTEN expression,
potentially uncovering a novel extrinsic, upstream mechanism of
MTSS1 regulation. Collectively, these data not only offer new insight
into the role and regulation of MTSS1 in suppressing tumor cell
invasion and migration but also uncover novel mechanisms of action of
both PTEN and the PDAC tumor microenvironment.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2017.10.004.
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